Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients.

822 Background: Docetaxel is one of the most active drugs for breast cancer. Impact of the Docetaxel in the adjuvant setting of breast cancer is being actively studied. METHODS We investigated that effect of sequential docetaxel and cyclophospahamide-doxorubicin combination. Patients with four and more positive axillary lymph node (ALN) were included to… (More)